Publications by authors named "Anchalee Avihingsanon"

Background: Simplified approaches to HCV treatment delivery are needed to meet elimination goals. However, the impact of low-touch strategies on individuals at higher risk due to treatment failure or reinfection is unknown. We estimated HCV reinfection rates, and the impact of resistance associated substitutions (RASs) on response in the ACTG A5360 (MINMON) trial.

View Article and Find Full Text PDF

Background: Twice-yearly subcutaneous lenacapavir has been shown to be efficacious for prevention of HIV infection in cisgender women. The efficacy of lenacapavir for preexposure prophylaxis (PrEP) in cisgender men, transgender women, transgender men, and gender-nonbinary persons is unclear.

Methods: In this phase 3, double-blind, randomized, active-controlled trial, we randomly assigned participants in a 2:1 ratio to receive subcutaneous lenacapavir every 26 weeks or daily oral emtricitabine-tenofovir disoproxil fumarate (F/TDF).

View Article and Find Full Text PDF

Background: Diagnostic delays for tuberculosis are common, with high resultant mortality. Urine-Xpert Ultra (Cepheid) could improve time to diagnosis of tuberculosis disease and rifampicin resistance. We previously reported on lot-to-lot variation of the Fujifilm SILVAMP TB LAM.

View Article and Find Full Text PDF
Article Synopsis
  • The Elecsys HCV Duo immunoassay can detect both antibodies to hepatitis C virus and HCV core antigen, showing strong diagnostic performance in blood donors.
  • The study involved blood samples from 100 healthy controls and 200 HCV-infected patients, assessing the assay's ability to diagnose active HCV infection and evaluate response to treatment with direct-acting antivirals.
  • Results indicated that the assay had high sensitivity and specificity for diagnosing HCV, with a 96.5% sustained virological response rate among treated patients, making it a useful tool for managing HCV in different populations, including those with HIV.
View Article and Find Full Text PDF
Article Synopsis
  • Chronic infection with Hepatitis B Virus (HBV) leads to weak virus-specific T cell responses, complicating viral clearance while causing significant liver inflammation due to immune responses.
  • A new assay developed for detecting HBV Capsid-Antibody Complexes (CACs) showed high accuracy in measuring these complexes in serum and linked them to increased liver inflammation and damage in chronic hepatitis B patients.
  • The study provides strong evidence that CACs play a key role in complement-mediated liver injury, establishing a new factor to consider alongside existing clinical markers for monitoring inflammation in chronic hepatitis B.
View Article and Find Full Text PDF

Tuberculosis is the most common opportunistic infection in individuals with HIV, and rifampicin is crucial in the treatment of tuberculosis. Drug-drug interactions complicate the use of DTG in HIV/TB co-infection, which makes drug administration more difficult. This study aimed to develop the population pharmacokinetic model of DTG when co-administered with rifampicin.

View Article and Find Full Text PDF

Objective: We studied the transition to dolutegravir-containing antiretroviral therapy (ART) at HIV treatment clinics within the International epidemiology Databases to Evaluate AIDS (IeDEA).

Design: Site-level survey conducted in 2020-2021 among HIV clinics in low- and middle-income countries (LMICs).

Methods: We assessed the status of dolutegravir rollout and viral load and drug resistance testing practices for patients on ART switching to dolutegravir-based regimens.

View Article and Find Full Text PDF

Malnutrition is a risk factor of sarcopenia in the elderly. During the COVID-19 pandemic, limited transportation and supply chain disruptions restricted access to nutritious foods. We assessed the nutritional status and sarcopenia risk in older people living with HIV (PLWH) on combination antiretroviral therapy in Thailand.

View Article and Find Full Text PDF

HCV RNA test determines current active infection and is a requirement prior to initiating HCV treatment. We investigated trends and factors associated with post-diagnosis HCV RNA testing rates prior to HCV treatment, and risk factors for first positive HCV RNA among people living with HIV (PLHIV) with HCV in the Asia-Pacific region. PLHIV with positive HCV antibody and in follow-up after 2010 were included.

View Article and Find Full Text PDF

Background: Semaglutide, a GLP-1 receptor agonist, is highly effective for decreasing weight. Concomitant loss of muscle mass often accompanies weight loss and may have consequences on muscle function.

Methods: This is a secondary analysis from the SLIM LIVER (ACTG A5371) study, a single-arm study of semaglutide in people with HIV (PWH) with metabolic dysfunction-associated steatotic liver disorder (MASLD).

View Article and Find Full Text PDF

Background: CD4 measurement is pivotal in the management of advanced HIV disease. VISITECT® CD4 Advanced Disease (AccuBio Limited, Alva, UK; VISITECT) is an instrument-free, point-of-care, semi-quantitative test allowing visual identification of a CD4 ≤200 cells/µl, or >200 cells/µl from finger-prick or venous blood.

Methods: As part of a diagnostic accuracy study of FUJIFILM SILVAMP TB LAM (clinicaltrials.

View Article and Find Full Text PDF

Sofosbuvir/Velpatasvir (SOF/VEL) is a combination drug used for chronic hepatitis C (HCV) infection. However, limited information exists regarding the pharmacokinetics of SOF/VEL and its metabolites in hemodialysis patients. We conducted a prospective investigation of the pharmacokinetic parameters of SOF/VEL after a single dose of SOF/VEL (400/100 mg) on days with and without dialysis in 12 Thai hemodialysis patients with chronic HCV infection, who had been undergoing hemodialysis for a duration of 0.

View Article and Find Full Text PDF

Introduction: Toxoplasma gondii can cause symptomatic toxoplasmosis in immunodeficient hosts, including in people living with human immunodeficiency virus (PLWH), mainly because of the reactivation of latent infection. We assessed the prevalence of toxoplasmosis and its associated risk factors in PLWH in the Asia-Pacific region using data from the TREAT Asia Human Immunodeficiency Virus (HIV) Observational Database (TAHOD) of the International Epidemiology Databases to Evaluate AIDS (IeDEA) Asia-Pacific.

Methods: This study included both retrospective and prospective cases of toxoplasmosis reported between 1997 and 2020.

View Article and Find Full Text PDF

There is an urgent need for rapid, non-sputum point-of-care diagnostics to detect tuberculosis. This prospective trial in seven high tuberculosis burden countries evaluated the diagnostic accuracy of the point-of-care urine-based lipoarabinomannan assay FUJIFILM SILVAMP TB LAM (FujiLAM) among inpatients and outpatients living with HIV. Diagnostic performance of FujiLAM was assessed against a mycobacterial reference standard (sputum culture, blood culture, and Xpert Ultra from urine and sputum at enrollment, and additional sputum culture ≤7 days from enrollment), an extended mycobacterial reference standard (eMRS), and a composite reference standard including clinical evaluation.

View Article and Find Full Text PDF
Article Synopsis
  • Ravidasvir (RDV) is a new drug that effectively inhibits the hepatitis C virus (HCV) replication and has shown promising results when combined with Sofosbuvir (SOF) in trials involving adults, including those co-infected with HIV.
  • In a study conducted in Thailand and Malaysia, RDV was given to both patients with and without cirrhosis for various durations, and pharmacokinetics (how the drug behaves in the body) were evaluated through blood sampling at different intervals.
  • The analysis revealed that RDV levels were influenced by several factors; however, these variations were not significant enough to impact the drug's effectiveness across the diverse group of participants, and there were no significant drug interactions for
View Article and Find Full Text PDF

In this randomised, controlled study in 14 low- and middle-income countries, individuals taking dolutegravir with darunavir/ritonavir for 48 weeks had a greater increase in systolic and diastolic blood pressure than individuals taking two nucleoside reverse transcriptase with darunavir/ritonavir. The difference remained significant after controlling for confounding factors including weight gain.

View Article and Find Full Text PDF
Article Synopsis
  • Non-sputum-based tests are crucial for diagnosing tuberculosis (TB) in people living with HIV (PWH), and the Kyn-to-Trp (K/T) plasma ratio may serve as a promising biomarker to predict TB disease in these patients on antiretroviral therapy (ART).
  • The study measured K/T ratios at three different time points (at diagnosis, 6 months before, and 6 months after) in PWH who developed TB, revealing significantly higher ratios at diagnosis compared to matched controls.
  • Following successful TB treatment, K/T ratios significantly dropped, but they increased in cases of treatment failure, suggesting the ratio could be useful for monitoring TB treatment in PWH, pending further validation studies.
View Article and Find Full Text PDF

Background: In people living with HIV-HBV, liver fibrosis progression can occur even with suppressive antiretroviral therapy (ART). We investigated the relationship between liver fibrosis and biomarkers of inflammation, apoptosis, and microbial translocation.

Methods: In this observational cohort study adults living with HIV-HBV already on effective ART were recruited in Australia and Thailand and followed for 3 years including 6 monthly clinical review and blood tests and annual transient elastography.

View Article and Find Full Text PDF

Introduction: Immune dysregulation persists in people with HIV (PWH) on antiretroviral therapy (ART) and may lead to accelerated vascular ageing and cardiovascular disease (CVD). While delayed time to initiation of ART has been linked to worse cardiovascular outcomes, the effect of ART initiation during acute infection on these outcomes is not well understood.

Methods: Participants were enrolled from the SEARCH010/RV254 acute HIV (AHI) and HIV-NAT chronic HIV (CHI) cohorts in Thailand.

View Article and Find Full Text PDF

This study aimed to assess second-line antiretroviral therapy (ART) outcomes in a National HIV Treatment program. People living with HIV aged ≥18 years initiating first-line ART who switched to second-line protease inhibitor-based regimens from January 2008 to May 2019, with a minimum of 1-year follow-up were studied. The primary outcome was second-line treatment failure (two consecutive virological failure episodes (viral load ≥1000 copies/mL)).

View Article and Find Full Text PDF